Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers

  title={Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers},
  author={Elisabetta Zucchi and Valentina Bonetto and Gianni Soraru' and Ilaria Martinelli and Piero Parchi and Rocco Liguori and Jessica Mandrioli},
  journal={Molecular Neurodegeneration},
Motor neuron diseases (MNDs) are etiologically and biologically heterogeneous diseases. The pathobiology of motor neuron degeneration is still largely unknown, and no effective therapy is available. Heterogeneity and lack of specific disease biomarkers have been appointed as leading reasons for past clinical trial failure, and biomarker discovery is pivotal in today’s MND research agenda. In the last decade, neurofilaments (NFs) have emerged as promising biomarkers for the clinical assessment… 

The Evolution of Neurofilament Light Chain in Multiple Sclerosis

The characteristics that make NfL a highly informative biomarker and depict the available technologies used for its measurement are discussed and the growing role of serum and CSF N fL in MS research and clinical settings is discussed.

Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis

This review examines the use of light chain neurofilaments (NFLs) as peripheral MS biomarkers in light of the current clinical and therapeutic evidence, MS immunopathology, and technological advances in diagnostic tools to highlight NFL multidimensional value as a reliable MS biomarker with a diagnostic-prognostic profile.

Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study

The stable longitudinal trajectory of pNfL supports its use as a marker of drug effect in clinical trials and has excellent diagnostic and prognostic performance for symptomatic patients with ALS.

Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion

A conceptual framework is provided for assessing the putative involvement of C9orf72 as a synaptopathy focusing on integrating mitochondrial and neuronal cytoskeleton degeneration as biomarkers and potential targets to treat ALS neurodegeneration.

Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?

An up-to-date state of the art of neuropsychological alterations in ALS is sought, tests used to detect cognitive and behavioral impairment are described, and promising non-invasive biomarkers to detect pre-clinical cognitive decline are focused on.

CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement

CSF pNfH is significantly higher inclassic and UMNp-ALS compared to UMN diseases with a better prognosis such as PLS and hSP, and its prognostic role is confirmed in classic and bulbar ALS, but not among U MNp, where clinical signs remained the only independent prognostic factors.

Microglia Influence Neurofilament Deposition in ALS iPSC-Derived Motor Neurons

Using induced pluripotent stem cells derived from a set of identical twin brothers discordant for ALS to assess the role of astrocytes and microglia on the expression and accumulation of neurofilament proteins in motor neurons found that motor neurons derived from the affected twin exhibited increased transcript levels of all three neurofilm isoforms and increased expression of phosphorylated neurofilm puncta.

Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS

It is demonstrated that CSF NfL and NfH as well as serum NFL are equally suited for the differential diagnosis of ALS, whereas serum N fH appears to be slightly less potent.

The 2022 Lady Estelle Wolfson lectureship on neurofilaments

The review of Nf across a spectrum of 87 diseases from all parts of medicine is followed by a critical appraisal of 33 meta‐analyses on Nf body fluid levels and considerations for clinical trial design and an outlook for future research.

Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction

It can be summarized that there is neuropathological evidence that protein aggregates of AD and PD are present both at the soma and the synapse, and a number of CSF and PET biomarkers beyond α-synuclein, tau and Aβ might capture these different faces of protein-related neurodegeneration.



Neurofilament light chain as a biomarker in neurological disorders

Evidence that both CSF and blood NfL may serve as diagnostic, prognostic and monitoring biomarkers in neurological diseases is progressively increasing, and N fL is one of the most promising biomarkers to be used in clinical and research setting in the next future.

Neurofilaments as biomarkers in neurological disorders

How technological advances have enabled the detection of neurofilament proteins in the blood is considered, and how these proteins consequently have the potential to be easily measured biomarkers of neuroaxonal injury in various neurological conditions are discussed.

Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis

Among all biomarkers, NfL yielded the highest diagnostic performance and was the best predictor of disease progression rate and survival in ALS and contribute to the understanding of the pathophysiological and electrophysiological correlates of biomarker changes.

Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients

Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients and their value as prognostic markers should be investigated further.

CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis

It is confirmed that CSF NF-L and pNF-H represent valuable diagnostic and prognostic biomarkers in ALS and were significantly increased when compared to CTL-1.

Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis

NF heavy and light chain levels have potential use as a marker of neural degeneration in ALS, but are not specific for the disease, and are more likely to be used as measures of disease progression.

Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival

The notion of CSF NFL as a useful tool for determining disease intensity in MND and FTD patients is strengthened and further studies in patient cohorts with clinically subtyped and genetically classified diagnoses are needed.

Biomarkers in Motor Neuron Disease: A State of the Art Review

This review highlights biomarkers that have emerged from the fields of systemic measurements including biochemistry (blood, cerebrospinal fluid, and urine analysis); imaging and electrophysiology, and gives examples of how a combinatorial approach may yield the best results.

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

The data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a possible surrogate to quantify effects of neuroprotective drugs in clinical trials.

Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS

Serum NfL may be considered a clinically validated prognostic biomarker for ALS and has potential utility as a pharmacodynamic biomarker of treatment effect, depending on the method used to estimate effect size.